REVIEWED BY
Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor
Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.
Dosage report — every number on this page is a published study dose, a registry or sponsor figure, a vendor certificate, a linked community report, or arithmetic. Peptide Insider does not recommend a dose. Reviewed against our editorial policy.
Citations verified against PubMed and ClinicalTrials.gov · Community data from 10 Reddit threads scanned comment by comment on September 16, 2026 · Published: 2026-09-16 · Last updated: 2026-09-16 · Research compounds, not medicine
MOTS-c dosage is a question with three honest answers, and none of them is a recommendation. We found no published study in which a human received native MOTS-c, so there is no clinical dose. A modified analog of it was given to 11 people with fatty liver at 25 mg a day for four weeks, against 9 on placebo, and that number exists. And some two thousand Reddit comments describe what people actually draw up, which clusters into two patterns that are easy to state. This page gives you all three, converts the 10 mg and 40 mg vials into syringe units, and labels which numbers were measured and which were typed.
Quick Answer
What people report: across ten Reddit MOTS-c threads (2,084 comments listed, 1,700 scanned, 372 containing an amount), the figures that recur most are 1 mg and 5 mg, and they belong to two different schedules: about 1 mg a day, often five days on and two off, or 5 mg two or three times a week. Stated weekly totals run from 5 mg to 15 mg; the daily reports cited below (about 1 to 4 mg a day) imply anything from 3 to 28 mg a week. On a U-100 syringe, 1 mg of a 10 mg vial in 2 mL is 20 units; 5 mg of a 40 mg vial in 2 mL is 25 units.
What the trials used: nothing, for MOTS-c itself — the only human dosing we found on record is CB4211, CohBar’s modified analog, at 25 mg once daily by subcutaneous injection for four weeks in 11 people with fatty liver against 9 on placebo (NCT03998514; topline results announced August 2021). A 120-person Phase 2 of native MOTS-c began in February 2026 and has not stated its dose (NCT07505745). The rodent studies used 5–15 mg per kilogram of body weight by injection (intraperitoneal where the abstract states a route).
The math: 10 mg in 1 mL is 10 mg/mL, so 10 units is 1 mg; 40 mg in 2 mL is 20 mg/mL, so 5 units is 1 mg and 25 units is 5 mg. Full tables for both vial sizes below; the MOTS-c calculator does any other combination.
Key Takeaways
- Two community patterns, not one number. The threads split between a low daily amount (about 1 mg, frequently five days on and two off) and a larger amount two or three times a week (usually 5 mg). A May 2026 r/NTNPerformance post asking how to dose it framed the choice as exactly that pair — a milligram a day or 5 mg twice a week — and 129 comments later that was still the shape of the answers. Neither pattern has been measured against anything.
- The only human dose is for a different molecule. CB4211 is an engineered analog of MOTS-c. Its 25 mg daily for four weeks lowered liver enzymes and glucose relative to placebo in a 20-person study; the topline results were announced by press release and selected for a liver-conference presentation but have not appeared as a peer-reviewed paper, and we found no later trial of the compound.
- Native MOTS-c has a trial running, and no number yet. The Hudson Biotech Phase 2a in prediabetes uses a fixed once-daily subcutaneous dose for 12 weeks; the registry does not say what it is. Primary completion is estimated for February 2027.
- Vial size changes everything about the arithmetic. Research MOTS-c comes as 10 mg and 40 mg vials; the tested lots we checked measured 10.3–10.6 mg and 41.4–42.8 mg. The same unit mark is four times the dose on a 40 mg vial reconstituted the same way. State the vial and the water before the units, every time.
- First-dose reactions are a recurring topic in the threads, at every amount. The most-commented MOTS-c thread in a year of Reddit search results is a report of anaphylaxis after a first 1 mg injection; another describes a week of palpitations after starting at 5 mg a week. Some posters describe test doses of a tenth to a quarter of a milligram. Everything here concerns a research compound sold strictly for non-human research use.
MOTS-c Dosage at a Glance: Reported vs Studied
| Source | Amount | Route & frequency | Duration | Evidence level |
|---|---|---|---|---|
| Community pattern A (10 threads) | ~1 mg (10 u of 10 mg in 1 mL; 20 u in 2 mL) | Subcutaneous, daily or five days on / two off | 4–8 weeks, then a break | Self-report, unverified |
| Community pattern B | 5 mg (50 u of 10 mg in 1 mL; 25 u of 40 mg in 2 mL) | Subcutaneous, 2–3× a week, often before training | 4–8 weeks, then a break | Self-report, unverified |
| Community range | 0.1–10 mg per injection; 3–15 mg per week | Daily to once weekly | — | Self-report, unverified |
| CB4211 (MOTS-c analog), human Phase 1b (NCT03998514) | 25 mg | Subcutaneous, once daily | 4 weeks; n = 11 vs 9 placebo | Randomized, placebo-controlled; press-release results only |
| CB4211, human Phase 1a | Six single-dose levels plus multiple-dose levels, none disclosed | Subcutaneous; single doses, then once daily | 7 days for the multiple-dose cohorts; 65 healthy adults | Doses not published (none found) |
| Native MOTS-c, human Phase 2a (NCT07505745) | Fixed dose, not stated | Subcutaneous, once daily | 12 weeks; n = 120 planned | Recruiting since Feb 2026; no results |
| Rat, vascular calcification (PMID 31694019) | 5 mg/kg | Injection (route not stated in abstract), daily | 4 weeks | Animal |
| Mouse, immobilization (PMID 38170165) | 15 mg/kg | Injection (route not stated in abstract), daily | 8 days | Animal |
| Mouse, cancer cachexia (PMID 42266945) | 15 mg/kg | Intraperitoneal, twice daily | Not stated in abstract | Animal |
| Aged mouse, healthspan (PMID 33473109) | Not stated in abstract | Treatment three times a week (route not stated in abstract) | From 23.5 months of age | Animal |
In This Guide
- What’s in a MOTS-c Vial: 10 mg, 40 mg, and What the Lots Measured
- MOTS-c Dosage Chart: 10 mg and 40 mg Vials in Syringe Units
- What People Report: 10 Threads, 2,000+ Comments
- How People Schedule It: Daily vs Two or Three Times a Week
- What the Studies Actually Used: One Analog Trial, One Pending, and the Rodents
- How the Animal Doses Scale — and Why That Is Not a Dose
- First Doses and Reactions: What the Threads Describe
- Reconstituting MOTS-c: Volumes, the Gel Problem, Storage
- Four Tells of an Invented MOTS-c Dosage Chart
- Where to Buy Lab-Tested MOTS-c
- Frequently Asked Questions
What’s in a MOTS-c Vial: 10 mg, 40 mg, and What the Lots Measured
MOTS-c is a single 16-amino-acid peptide encoded inside the mitochondrial genome, first described in mice in 2015 (PMID 25738459). Unlike the blends covered in our KLOW dosage report, there is no component split to worry about: a milligram of MOTS-c is a milligram of one molecule. What varies is the vial. The vendor we checked sells it in two sizes, and the size decides the arithmetic on every line below.
Amino Club lists MOTS-c as a 10 mg vial and a 40 mg vial, and publishes a per-lot certificate for each from ILS Laboratories, an ISO/IEC 17025-accredited testing lab. The four certificates on the product page when we checked it on September 16, 2026: 10 mg lot MTC0003 (tested July 30, 2026) measured 10.62 mg of peptide at 99.81% purity; 10 mg lot MTC0001 (May 29, 2026) measured 10.34 mg at 99.53%; 40 mg lot MTC0004 (July 30, 2026) measured 42.79 mg at 99.88%; and 40 mg lot MTC0002 (May 29, 2026) measured 41.39 mg at 99.39%. The lot MTC0004 certificate also reported identity confirmed by HPLC, heavy metals not detected and no growth on sterility testing; the others list seven to eight assays passed. The overfill matters a little: a “40 mg” vial that holds 42.8 mg is 7% stronger than the label, which is within the rounding of any syringe but worth knowing if you are the kind of person who reads certificates. Our guides to reading a certificate of analysis and independent lab testing explain what a single-peptide certificate must show.
The threads reflect the same two formats. The 40 mg vial is the one people mention most when they talk about cost — one r/Biohacking commenter noted that daily use gets expensive on anything smaller than a 30 or 40 mg vial and said they would buy 40 mg next time (r/Biohacking, August 2026), and another in the same thread described a vendor selling ten 40 mg vials for about $170. A 20 mg vial appears occasionally (r/NTNPerformance, May 2026). The 10 mg vial is the format the existing MOTS-c for weight loss guide priced at $40–70; Amino Club’s 10 mg was listed at $39.99 and its 40 mg at $134.99 on the day we checked.
MOTS-c Dosage Chart: 10 mg and 40 mg Vials in Syringe Units
This is the only part of the topic with exact answers. Units below are for a standard U-100 insulin syringe (100 units = 1 mL). The rows are common reconstitution volumes chosen for arithmetic convenience — 1–3 mL for a 10 mg vial, 1–3 mL for a 40 mg vial — and the columns are amounts that appear in the threads. Cells of 100 units or more exceed a U-100 syringe and would need a second draw or a larger syringe. The bold cells are the two community patterns, 1 mg and 5 mg. The MOTS-c dosage calculator marks the barrel for any other combination, and the general peptide calculator handles any vial size.
10 mg vial
| BAC water added to 10 mg | Concentration | 0.5 mg | 1 mg | 2 mg | 2.5 mg | 5 mg |
|---|---|---|---|---|---|---|
| 1 mL | 10 mg/mL | 5 u | 10 u | 20 u | 25 u | 50 u |
| 2 mL | 5 mg/mL | 10 u | 20 u | 40 u | 50 u | 100 u |
| 3 mL | 3.3 mg/mL | 15 u | 30 u | 60 u | 75 u | 150 u |
40 mg vial
| BAC water added to 40 mg | Concentration | 1 mg | 2 mg | 2.5 mg | 5 mg | 10 mg |
|---|---|---|---|---|---|---|
| 1 mL | 40 mg/mL | 2.5 u | 5 u | 6.25 u | 12.5 u | 25 u |
| 2 mL | 20 mg/mL | 5 u | 10 u | 12.5 u | 25 u | 50 u |
| 3 mL | 13.3 mg/mL | 7.5 u | 15 u | 18.75 u | 37.5 u | 75 u |
Two things fall out of the tables. First, the same syringe mark means very different amounts depending on the vial: 10 units is 1 mg from a 10 mg vial in 1 mL but 2 mg from a 40 mg vial in 2 mL. This is where the thread arithmetic most often goes wrong — one r/NTNPerformance commenter wrote that a 10 mg/mL bottle means 50 units for the dose, which is 5 mg, without saying what dose they meant (r/NTNPerformance, May 2026). Second, the 5 mg pattern on a 10 mg vial in 1 mL is a 50-unit draw, half the syringe; the one poster in our log who explained buying the 40 mg format was on a daily schedule and cited cost.
How many injections a vial gives
| Amount per injection | Injections per 10 mg vial | Injections per 40 mg vial |
|---|---|---|
| 0.5 mg | 20 | 80 |
| 1 mg | 10 | 40 |
| 2 mg | 5 | 20 |
| 2.5 mg | 4 | 16 |
| 5 mg | 2 | 8 |
| 10 mg | 1 | 4 |
What People Report: 10 Threads, 2,000+ Comments
We pulled ten MOTS-c threads from the past year in which dosing was discussed, selected from the most-commented search results across r/Biohacking, r/Biohackers, r/BodyHackGuide, r/NTNPerformance and r/PeptideForum — 2,084 comments listed by Reddit, 1,700 of them returned by the API and scanned — and extracted every comment containing a milligram, microgram or unit figure: 372 comments. The tally counts the first figure in each comment, so a minority of them refer to something else in the poster’s stack (retatrutide and NAD+ doses turn up in the same sentences, and a few posters describe 5-amino-1MQ alongside), and we read the high-scoring comments individually to correct for that. The verbatim log with comment scores is on file; here we paraphrase, link every thread, and quote one fragment.
The distribution. 1 mg appeared as the first figure in 94 dose comments, 5 mg in 76, 2 mg in 45, 10 mg in 30, 3 mg in 14, 0.5 mg in 13 and 4 mg in 11. Everything else — 0.1, 0.25, 1.5, 2.5, 6, 7.5 and 15 mg — appeared six times or fewer. The frequency words that accompany those figures split the same way: daily or a days-on-days-off pattern in 51 comments, three times a week (usually Monday, Wednesday, Friday) in 32, a stated weekly total in 20, twice a week in 15, every other day in 5, and before-training timing in 6.
Pattern A: about 1 mg, most days. The r/NTNPerformance dosing question that anchors this pattern opened by saying the common approach seemed to be “either 1mg daily or 5mg twice a week” (r/NTNPerformance, May 2026). Among its replies: one poster had run a first cycle at 1 mg every day and was heading into the second week of a second at 5 mg three times a week; another finished a cycle at 1 mg five days a week, injected about half an hour before a workout or run; a third described 4 mg daily with no complaints. The same low-daily pattern is the standard piece of advice in the reaction threads: the highest-scoring dose reply to a poster who started at 5 mg a week and spent it with palpitations was to use 1 mg a day, five days on and two off, and to stop if reactions continued (r/Biohacking, August 2026); the highest-scoring reply to a poster who found 2 mg too much was to drop to 1 mg a day rather than quit (r/BodyHackGuide, April 2026). In a longer-term thread the highest-scoring dose comment described 1 mg on Monday, Wednesday and Friday, cycles of four to eight weeks, and a washout between them (r/NTNPerformance, August 2026); another poster there described 2.7 mg daily.
Pattern B: 5 mg, two or three times a week. The same threads carry the opposite camp. In the dosing thread, a 5-point comment argued for 5–10 mg three times a week as the only dosing that gives results, allowed for starting lower to assess tolerance, and was dismissive of small daily amounts; a 3-point comment put the ideal at 2–5 mg three times a week and claimed daily use reduced the effect; and one poster who tried 5 mg three times a week described feeling very fatigued at 5 mg and backing down to 3 mg three times a week (r/NTNPerformance, May 2026). In a four-week write-up thread, the second-highest-scoring dose comment described 5 mg twice a week for two weeks and then 5 mg every other day, and another described 5 mg about 45 minutes before resistance training three times a week (r/BodyHackGuide, March 2026); the original post in that thread reads like marketing — it mentions finalizing a streamlined protocol — so we used only its comments. In the longer-term thread, a commenter said many people feel nothing at 2 mg and need 5 mg two or three times a week; another had settled at 5 mg twice a week; a third checked the arithmetic of 5 mg three times a week and got 15 mg a week (r/NTNPerformance, August 2026). One poster in a June thread about how fast the effect arrived had moved from an every-other-day approach to 10 mg once a week and said it seemed to help more (r/BodyHackGuide, June 2026).
The weekly total is where the two camps overlap. A November 2025 r/PeptideForum newcomer said the recommended amount they kept seeing was 5–15 mg a week split into two or three injections (r/PeptideForum, November 2025); the April 2026 poster who started at 2 mg had read 5–10 mg a week (r/BodyHackGuide). Pattern A at 1 mg five days a week is 5 mg a week; Pattern B at 5 mg twice a week is 10 mg. The threads are arguing about the shape of the week more than the size of it.
The low end is bigger than it looks. Thirteen comments put 0.5 mg as the first figure and nine put 0.1 or 0.25 mg. Many are test doses and ramps, though a few posters describe 100–500 µg as their regular amount. In the reaction threads, some posters describe trying a tenth of a milligram or less the first time with any new peptide, and one described a quarter-milligram trial before anything else (r/Biohackers, April 2026). In the r/PeptideForum thread one commenter described building up from 250 µg and having trouble sleeping, and another advised 500 µg a day and described the effect of higher amounts as disorienting (r/PeptideForum). A German-language reply in the 5 mg thread told the poster to start at 0.5 mg three times a week and go up slowly (r/Biohacking).
What the reports do not contain. We found no comment among the 1,700 scanned that reported a measurement — glucose, lactate, VO₂ or body composition beyond the scale. The positive reports are about perceived energy, easier cardio, and running distances that improved while the poster was also, in at least two cases, on tesamorelin, and often alongside retatrutide. The negative reports — no effect at 1–2 mg, no effect at 6 mg four days a week, lumps at the injection site at every amount tried — are just as unmeasured. Two 2026 r/Biohacking threads asking, in their titles, whether MOTS-c is a scam and whether it is snake oil drew 184 and 177 comments (September 2026, June 2026); neither is a dosing thread, and we did not mine them, but the question they ask is the one none of the dosing threads can answer, because we found nothing measured in any of them.
How People Schedule It: Daily vs Two or Three Times a Week
The table lists the schedules that appear in the threads, with the weekly total each implies and how long one vial lasts at that rate. The last two columns are arithmetic, not observation, and assume no loss to dead space or discarded vials. Every row is a description of what someone posted; none is a recommendation, and none has been compared with any other in a study.
| Schedule people describe | Weekly total | One 10 mg vial lasts | One 40 mg vial lasts | Threads |
|---|---|---|---|---|
| About 1 mg every day | 7 mg | 1.4 weeks | 5.7 weeks | r/NTNPerformance, r/Biohacking, r/BodyHackGuide |
| 1 mg, five days on, two off | 5 mg | 2 weeks | 8 weeks | r/Biohacking, r/BodyHackGuide |
| 1 mg Monday / Wednesday / Friday | 3 mg | 3.3 weeks | 13.3 weeks | r/NTNPerformance |
| 2 mg, five days on, two off | 10 mg | 1 week | 4 weeks | r/BodyHackGuide, r/BodyHackGuide |
| 5 mg twice a week | 10 mg | 1 week | 4 weeks | r/NTNPerformance, r/NTNPerformance, r/BodyHackGuide |
| 5 mg three times a week (before training) | 15 mg | 0.7 weeks | 2.7 weeks | r/NTNPerformance, r/BodyHackGuide, r/Biohacking |
| 10 mg once a week | 10 mg | 1 week | 4 weeks | r/BodyHackGuide |
| Ramp: 0.5 mg, then 1, 2, up to 4 mg over weeks | varies | — | — | r/NTNPerformance, r/BodyHackGuide, r/BodyHackGuide |
Cycle length. Four weeks is the cycle length that recurs in the comments we read (the March write-up thread, the poster who ran 2 mg five days on and two off for four weeks), with four to eight weeks and then a washout described in the longer-term thread, and one comment there claiming people who use high amounts take up to four months off — a claim with nothing behind it that we could find (r/NTNPerformance, August 2026). The four-week figure is worth noticing because it is also the length of the only human study; whether that is where the convention came from, we cannot tell.
Timing. Injecting 30–45 minutes before training is described in both camps — the half-hour report comes from a 1 mg, five-days-a-week poster, the 45-minute report from a 5 mg, three-times-a-week poster — and we found no rationale beyond how it felt. The immobilization mouse study injected daily without reference to activity (PMID 38170165).
Ramping. Several posters describe building up week by week — 1 mg, then 2.5, 3, 3.5 and 4 mg over five steps, the first three a week apart, in one account; 1 mg up to 4 mg on what the poster called a bi-weekly schedule in another; 5 mg twice a week for two weeks and then every other day in a third. The ramp is the one place where the daily and the twice-weekly camps agree with each other and with the reaction threads: whatever the target, the first injections people describe are smaller than it.
What the Studies Actually Used: One Analog Trial, One Pending, and the Rodents
We found no published study that gave native MOTS-c to a human and reported the dose. The human MOTS-c literature — dozens of papers — measures the peptide as a circulating biomarker: it rises after a bout of endurance exercise (PMID 34351816), changes with training in breast-cancer survivors (PMID 34413391), was measured in breast-cancer patients randomized to metformin (PMID 36490309) and in diabetics after coronary revascularization (PMID 32052315), and shifts with repeated heat exposure during limb immobilization (PMID 40674654). None of those studies injected it. Two interventional programs exist. One used a modified analog and published its dose by press release; the other uses the native peptide and has not published anything.
CB4211: a MOTS-c analog at 25 mg a day for four weeks
CohBar’s CB4211 is described by the company as a novel and improved analog of MOTS-c — an engineered variant, not the peptide sold in research vials. It went through a Phase 1a/1b randomized, double-blind, placebo-controlled study registered as NCT03998514, which ran from July 2018 to April 2021 and enrolled 88 people by the registry’s count. The Phase 1a portion was a single- and multiple-ascending-dose study in healthy non-obese adults: six single-dose cohorts — five of six on drug and two on placebo, one of a single subject on each — then multiple-dose cohorts of six and two injected once daily for seven days. The registry lists the single-dose levels only as Dose 1 through Dose 6 and the multiple-dose levels as to be determined, and we found no disclosure of them; its press release put the Phase 1a total at 65 healthy adults.
The Phase 1b portion is the number that matters. Twenty adults with obesity and non-alcoholic fatty liver disease — at least 10% liver fat at enrollment — were randomized at four sites to 25 mg of CB4211 or placebo, injected subcutaneously once daily for four weeks, 11 on drug and 9 on placebo. CohBar’s topline announcement of August 10, 2021 reported that ALT fell 21% on CB4211 against a 4% rise on placebo, AST fell 28% against 11%, and glucose fell 6% against no change, each difference reaching p<0.05; liver fat fell about 5% in both arms, which the company called comparable; body weight showed a trend lower but no figure was given; and the only adverse events in more than 10% of treated subjects were transient, generally mild-to-moderate injection-site reactions (CohBar press release, GlobeNewswire). The results were selected for a late-breaker presentation at The Liver Meeting 2021. We found no peer-reviewed publication of them, no results posted to the registry, and no other CB4211 trial in the registry; a PubMed search for the compound name returns nothing. So the only human dose of anything MOTS-c-shaped is 25 mg a day of a different molecule, in 11 people, for a month, reported by the sponsor.
Native MOTS-c: a Phase 2 that started in 2026 and has not reported
In February 2026 a Phase 2a trial of MOTS-c itself began recruiting at Peking University Shenzhen Hospital, sponsored by Hudson Biotech (NCT07505745). It plans to randomize 120 adults with prediabetes and overweight or obesity to MOTS-c or placebo, each with standardized lifestyle counselling, as a fixed once-daily subcutaneous dose for 12 weeks, with insulin sensitivity on an oral glucose tolerance test as the primary endpoint and safety follow-up to week 16. The registry does not state the dose. Primary completion is estimated for February 2027 and study completion for May 2028. Until it reads out, “MOTS-c dosage” has no human number behind it.
What the animal studies used
The rodent literature is where every MOTS-c dose figure ultimately comes from, and its doses are in milligrams per kilogram of body weight, by injection — intraperitoneal where an abstract states the route. The recurring amounts: 5 mg/kg once a day for four weeks in rats with induced vascular calcification (PMID 31694019); 5 mg/kg (frequency and route not stated in the abstract) in a mouse model of placental injury (PMID 41268602); 15 mg/kg a day for eight days in immobilized mice, where muscle loss was about 5% instead of 15% (PMID 38170165); 15 mg/kg daily for three weeks in diabetic rats (PMID 40661667); and 15 mg/kg twice a day, intraperitoneally, in a mouse cancer-cachexia model (PMID 42266945). The 2021 study that made MOTS-c an “exercise mimetic” gave it three times a week to 23.5-month-old mice and reported longer healthspan and better physical capacity (PMID 33473109); the 2015 paper that first described its metabolic effects in mice is the origin of the whole field (PMID 25738459). Neither of those two abstracts states the milligram-per-kilogram amount.
How the Animal Doses Scale — and Why That Is Not a Dose
A tempting shortcut is to multiply a rodent mg/kg dose by your own body weight. That arithmetic is wrong in a known direction, and the correct version is public: the FDA’s 2005 guidance on first-in-human starting doses converts animal mg/kg to a human-equivalent mg/kg by body surface area, dividing a mouse dose by 12.3 and a rat dose by 6.2 (FDA, Estimating the Maximum Safe Starting Dose, July 2005, Table 1). Applied to the MOTS-c studies for scale only: the 5 mg/kg mouse dose becomes about 0.4 mg/kg, or roughly 28 mg for a 70 kg adult; the 5 mg/kg rat dose becomes about 0.8 mg/kg, or roughly 56 mg; the 15 mg/kg mouse dose becomes about 1.2 mg/kg, or roughly 85 mg; the 15 mg/kg rat dose becomes about 2.4 mg/kg, or roughly 170 mg. The guidance then applies a default safety factor of ten before anyone is dosed, and it is a method for choosing the first dose of a trial, not for choosing anything else.
Set the three sets of numbers side by side and the picture is clear. The surface-area-scaled animal doses land in the tens to low hundreds of milligrams a day. The one human trial of an analog used 25 mg a day. The community patterns are 1 mg a day or 5 mg two or three times a week — roughly five to more than a hundred times below the scaled animal figures and a fraction of the analog dose. Whatever people are feeling at those amounts, it is not the exposure the animal studies produced, and no experiment has looked at whether anything happens at a milligram.
KEY TAKEAWAY
A milligram-per-kilogram rodent dose does not become a human dose by multiplying by body weight — species scale by surface area and metabolism, not mass — and the animal studies used injection, daily or twice daily, for days to a few weeks. The scaled figures above are context for reading the threads, not a dose; every human MOTS-c number we have seen online traces to the rodent data, to the CB4211 press release, or to nothing.
First Doses and Reactions: What the Threads Describe
The most-commented MOTS-c thread in a year of Reddit search results is not about results. It is an April 2026 r/Biohackers post from someone writing from a hospital after their first injection — 1 mg — describing what they called anaphylaxis within five minutes, and, in a later edit, 18 hours in emergency care that week (r/Biohackers, April 2026, 764 comments). The highest-scoring reply that names an amount, at 110 points, asked whether that was really a first dose and what the symptoms were; a 13-point reply said 1 mg had also gone badly for them; a 9-point reply questioned whether the vial actually contained 1 mg of what the label said; and a 7-point reply made the case that any new peptide should be tried first at 100 µg or less. Nothing in the thread was verified, including the diagnosis, and a research vial’s identity is exactly the thing a certificate exists to establish. Test doses of about a tenth of a milligram appear in other threads as well.
The other reaction reports are about amount rather than allergy. The poster who started on 5 mg a week described a week of fidgeting, palpitations they compared to four shots of espresso, and what felt like a daily anxiety attack (r/Biohacking, August 2026). In the four-week thread an 8-point comment described 5 mg producing the reverse of the expected effect — repeated yawning and stretching — and a retreat to 1 mg (r/BodyHackGuide, March 2026). Fatigue at 5 mg appears in the dosing thread; trouble sleeping and a disoriented feeling at higher amounts in the r/PeptideForum thread; injection-site lumps at 1, 2 and 5 mg in the June thread. The 5 mg camp’s own advice, repeated across threads, is to start lower and build up. Both camps, in other words, describe the same first week: less than the target, and watching.
Against that, a recurring report at 1–2 mg is nothing at all — no energy change, no endurance change — which is what sends people toward 5 mg in the first place. A page that only listed the reactions would misrepresent the threads as badly as one that only listed the successes. We have no MOTS-c side-effects page yet; the closest analogs on this site are SS-31 (elamipretide) side effects, another mitochondrial peptide with actual trial data, and humanin side effects, which has none. Posters stacking MOTS-c with retatrutide, which turns up throughout these threads, or with 5-amino-1MQ and NAD+, which a few describe, cannot attribute anything to one compound.
Reconstituting MOTS-c: Volumes, the Gel Problem, Storage
The tables above assume 1–3 mL of bacteriostatic water in a 10 mg vial and 1–3 mL in a 40 mg vial, drawn with a U-100 insulin syringe; the one reconstitution volume stated in our log is 2 mL in a 20 mg vial, and one commenter referred to a 10 mg/mL solution. At 10 mg in 1 mL, the 1 mg pattern is a 10-unit draw and the 5 mg pattern is 50 units; at 40 mg in 2 mL they are 5 and 25 units. Nothing about those volumes is specified by any study — the rodent papers injected by weight at concentrations irrelevant to a syringe — so the choice is convenience, and the tables above cover the common ones. Our bacteriostatic water guide covers the diluent itself.
MOTS-c has one reconstitution problem the other peptides on this site mostly do not: it turns to gel. A January 2026 r/BodyHackGuide post described a vial that was normal on the first day and had a gel-like consistency on the second, despite being stored in a cool place and having its top disinfected before and after use, as the poster described it (r/BodyHackGuide, January 2026, 163 comments). The replies split between blaming the water — a 5-point reply asked whether a pharmaceutical-brand bacteriostatic water had been used, and a 5-point answer said the vendor’s own water had been used instead — and describing a workaround: reconstituting with a dilute acetic acid solution, or a mix of acetic acid water and bacteriostatic water, which one commenter identifying as a vendor said they always recommend for their 40 mg vials. Another commenter argued that bacteriostatic water’s near-neutral pH is the reason. One poster said the gel could not be drawn up and that they had lost two vials to it; another described the same thing happening to a tirzepatide vial; one said they had gone through two kits of MOTS-c without ever seeing it. We found no published data on MOTS-c solubility or solution stability at these concentrations, so the mechanism claims in the thread are unverified; the observation that it happens is well attested.
Storage claims follow the usual pattern. A comment in the dosing thread said the reconstituted peptide is only good for seven days, and noted that at the amount under discussion a 10 mg vial would last two weeks — a conflict the thread did not resolve (r/NTNPerformance, May 2026). One poster in a stacking thread mentioned keeping twenty 40 mg vials in a freezer. We found no stability study of MOTS-c in solution and the vendor we checked does not publish one; the certificates cover the lyophilized powder as shipped. The lot certificates above list the sample matrix as lyophilized and one lists a 3 mL vial volume, which is the container, not a reconstitution instruction.
Four Tells of an Invented MOTS-c Dosage Chart
Dosage charts for MOTS-c circulate on vendor sites and in the threads, and they are more confident than the evidence allows. Four features identify a chart that was typed rather than derived. First, tiers. Beginner, intermediate and advanced columns imply a dose-response curve; no dose-response study of MOTS-c exists in humans, and each rodent abstract we read states a single fixed amount. Second, a precise weekly total presented as established. The 5–15 mg a week figure that newcomers arrive with is a community convention; its two halves (about 1 mg daily versus 5 mg twice weekly) come from different camps who disagree with each other, and nobody measured either. Third, a cycle length with a reason attached. Four weeks on and a break is what people describe; the only human study lasted four weeks because that was its design, not because anything was learned about week five. Fourth, citations that point to the mouse papers as if they supported the milligram amounts. The rodent doses, scaled properly, are tens of milligrams a day for a human; a chart that lists 1–5 mg and footnotes the 2015 Cell Metabolism paper is citing a study whose abstract states no dose at all. A chart that passes all four tests will look like the tables on this page: arithmetic on one side, attributed reports on the other, and a trial section that admits how little it contains.
Where to Buy Lab-Tested MOTS-c
Because MOTS-c is a single peptide, the certificate question is simpler than for a blend, but the anaphylaxis thread above is a reminder of why it still matters: the only way to know that a vial labelled 10 mg of MOTS-c contains 10 mg of MOTS-c and nothing else is a lot-specific certificate from an accredited lab that confirms identity, quantifies content and screens for contaminants. Amino Club lists MOTS-c 10 mg at $39.99 and 40 mg at $134.99 and publishes exactly that document for each lot — the four we read are summarized above, with measured content of 10.34–10.62 mg and 41.39–42.79 mg and purity of 99.4–99.9%; on September 16, 2026 its product page showed a 20% saving with code 15OFF. Sale banners come and go; the certificates are the constant.

Looking for Lab-Tested MOTS-c?
Our top-rated vendor publishes per-lot certificates from an ISO/IEC 17025 laboratory — identity, measured content, purity, sterility and endotoxin for every batch of its 10 mg and 40 mg vials — and offers up to 30% off your first order.
Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.
Frequently Asked Questions
What is the most common MOTS-c dosage people use?
There are two, not one. Across ten Reddit threads with 1,700 comments scanned, the figures that appear most are 1 mg and 5 mg, attached to different schedules: about 1 mg a day, often five days on and two off, or 5 mg two or three times a week. Both are descriptions of what people post, not studied or recommended doses; no human study of MOTS-c has published a dose.
How many units is a MOTS-c dose on an insulin syringe?
It depends on the vial and the water. With 10 mg in 1 mL, 10 units is 1 mg and 50 units is 5 mg; in 2 mL, 20 units is 1 mg. With 40 mg in 2 mL, 5 units is 1 mg and 25 units is 5 mg; in 1 mL, 2.5 units is 1 mg. The same syringe mark is four times the amount on a 40 mg vial reconstituted with the same volume, so state the vial and volume before the units.
Has MOTS-c ever been dosed in humans?
Not the native peptide, in any published study. CohBar’s CB4211, an engineered analog, was given at 25 mg once daily by subcutaneous injection for four weeks to 11 people with fatty liver against 9 on placebo, with results announced by press release in 2021. A Phase 2a trial of native MOTS-c in 120 adults with prediabetes began in February 2026 with a fixed once-daily dose the registry does not state; its primary completion is estimated for February 2027.
How much MOTS-c did the animal studies use?
Typically 5 mg/kg or 15 mg/kg of body weight, by injection (intraperitoneal where the abstract states a route), once or twice daily for eight days to four weeks. Converted by the FDA’s surface-area method, those are roughly 0.4–2.4 mg/kg human-equivalent — about 30 to 170 mg for a 70 kg adult — which is far above anything described in the threads. The conversion is for scale, not a dose.
How long does a MOTS-c vial last?
Arithmetic: a 10 mg vial gives 10 injections at 1 mg or 2 at 5 mg; a 40 mg vial gives 40 at 1 mg or 8 at 5 mg. At 1 mg five days a week, a 10 mg vial is two weeks and a 40 mg vial is eight; at 5 mg twice a week, they are one week and four. We found no stability study of reconstituted MOTS-c.
Why does MOTS-c turn into a gel after reconstitution?
Nobody has published the answer. A 163-comment thread describes a vial that gelled overnight; commenters blamed the bacteriostatic water’s source or its near-neutral pH and described reconstituting with dilute acetic acid or an acetic-acid-and-bacteriostatic-water mix as a workaround, and one commenter identifying as a vendor said they recommend that for their 40 mg vials. One poster said a gelled vial could not be drawn up and was thrown out. We found no solubility or stability data for MOTS-c at these concentrations.
Is there a MOTS-c dosage chart?
Many circulate; none is derived from an experiment. This page’s chart is arithmetic — 10 mg and 40 mg vials converted to syringe units at each common water volume — next to the amounts people report and the one analog trial dose. Charts with beginner, intermediate and advanced tiers were constructed, not measured, and charts that footnote the mouse papers are citing doses tens of times larger than the ones they list.
What do people report at their first MOTS-c dose?
The most-commented MOTS-c thread in a year of Reddit search results describes anaphylaxis after a first 1 mg injection; others describe palpitations after starting at 5 mg a week, fatigue at 5 mg, disrupted sleep at higher amounts, injection-site lumps, and — very commonly at 1–2 mg — nothing at all. Some posters describe a test dose of about 0.1–0.25 mg before anything else. None of this is verified, and a lot-specific certificate is the only check on what a vial actually contains.
Bottom Line
MOTS-c dosage has a community answer, an analog answer and a scientific answer, and they sit at three different scales. The community answer is either about 1 mg most days or 5 mg two or three times a week, in four-to-eight-week runs, a pair of conventions that argue with each other in every thread and that nobody has measured. The analog answer is 25 mg a day for four weeks of a different molecule, in 11 people, reported by its sponsor and not, as far as we could find, published in a journal. The scientific answer for MOTS-c itself is that no human dose exists yet, that the rodent doses scale to tens or hundreds of milligrams, and that the first trial capable of producing a number is recruiting now with a completion date in 2027. What you can know exactly is the arithmetic, and the one document worth insisting on is a lot-specific certificate, because the most-commented thread in a year of search results is about a first injection whose contents nobody could confirm.
Disclaimer
This page reports published study doses, a sponsor’s announced trial results, aggregated public self-reports and arithmetic. It does not recommend a dose, schedule or route. MOTS-c is not an approved drug and is sold strictly for non-human research use; nothing here is medical advice. Community reports are unverified and linked to their sources. See our full medical disclaimer.
References
- A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease — ClinicalTrials.gov NCT03998514 (CohBar; completed April 2021; n = 88; dose levels undisclosed; no results posted)
- CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 — press release, August 10, 2021 (25 mg once daily × 4 weeks; n = 11 vs 9)
- MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity — ClinicalTrials.gov NCT07505745 (Hudson Biotech; Phase 2a; recruiting; n = 120 planned; dose not stated)
- Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers — FDA, July 2005 (Table 1 conversion factors)
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance — Cell Metab, 2015 (PubMed; mouse)
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis — Nat Commun, 2021 (PubMed; mouse and human biomarker)
- Mitochondrial-derived peptide MOTS-c attenuates vascular calcification and secondary myocardial remodeling via AMPK signaling — Cardiorenal Med, 2020 (PubMed; rat; 5 mg/kg once a day × 4 weeks)
- MOTS-c protects against placental injury via Nrf2 activation in hypoxia-induced intrauterine growth restriction mice — Int J Mol Med, 2026 (PubMed; mouse; 5 mg/kg)
- Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration — Am J Physiol Endocrinol Metab, 2024 (PubMed; mouse; 15 mg/kg daily × 8 days)
- Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart — Front Physiol, 2025 (PubMed; rat; 15 mg/kg daily × 3 weeks)
- MOTS-c partially protects against skeletal muscle deterioration in C26 cachexia — Front Med, 2026 (PubMed; mouse; 15 mg/kg twice daily)
- Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans — J Appl Physiol, 2021 (PubMed; biomarker)
- Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors — Sci Rep, 2021 (PubMed; biomarker)
- Circulating levels of MOTS-c in patients with breast cancer treated with metformin — 2022 (PubMed; biomarker)
- β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease — 2020 (PubMed; biomarker)
- Repeated heat stress modulates the levels of the mitokines MOTS-c and FGF21 in active men during calf muscle immobilization — Med Sci Sports Exerc, 2025 (PubMed; biomarker)